| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V122259 | (S,R,S)-BBO-11818 | 3029184-80-0 | (S,R,S)-BBO-11818 is a KRAS inhibitor that can be used in cancer research. |
|
V51476 | CFL-137 | 708-06-5 | CFL-137 is a selective KRasG12C inhibitor. |
|
V128345 | ADT-1004 | 1945941-72-9 | ADT-1004 is the oral active prodrug of ADT-007. |
|
V11400 | Antineoplaston A 10 | 91531-30-5 | Antineoplaston A10 exists naturally in the human body and is an inhibitor (blocker/antagonist) of Ras. |
|
V51547 | Antitumor compound 5a | 2907704-65-6 | Antitumor compound 5a, has an IC50 value of 2.62 µM, meaning that it inhibits MCF-7 breast cancer cells. |
|
V3974 | ARS-1620 | 1698055-85-4 | ARS-1620 is a novel, potent, orally bioavailable and covalent inhibitor ofKRASG12C with antitumor activity. |
|
V1902 | BQU57 | 1637739-82-2 | BQU57, a derivative of RBC8, is a novel and selective GTPase Ral inhibitor relative to the GTPases Ras and RhoA. |
|
V3118 | CCG-203971 | 1443437-74-8 | CCG-203971 is a novel, 2nd generation small-molecule inhibitor of the Rho/MRTF/SRF [RhoA/myocardin-related transcription factor A (MRTF-A)] pathway with an IC50 value of 0.64 μM for SRE. |
|
V51194 | Daraxonrasib (RMC-6236) | 2765081-21-6 | Daraxonrasib (RMC-6236; RAS-IN-2; RMC6236;Compound A122) is a potent RAS(ON)MULTI inhibitor that may be utilized in cancer-related research. |
|
V143850 | Daraxonrasib racemate (RMC‑6236; RAS-IN-4) | 2765091-21-0 | Daraxonrasib racemate (RMC‑6236; RAS-IN-4) is a RAS inhibitor with anti-tumor activity. |
|
V86765 | HRS-4642 | 3033864-81-9 | HRS-4642 is a selective KRAS(G12D) inhibitor (Kd=0.083 nM) with anti-cancer activity. |
|
V138094 | ISIS 2503 sodium scrambled negative control | The ISIS 2503 sodium scrambled negative control is a negative control with the sequence of ISIS 2503 sodium salt scrambled. | |
|
V2420 | K-Ras inhibitor 6 | 2060530-16-5 | K-Ras (G12C) inhibitor 6 is a novel, potent, allosteric, irreversible,/covalent cysteine-reactive small molecule KRAS G12C inhibitor with anticancer activity. |
|
V2944 | K-Ras-IN-1 | 84783-01-7 | K-Ras-IN-1 (formerly known as K-Ras-Inhibitor-1) is a novel small molecule K-Ras inhibitor that binds to K-Ras in a hydrophobic pocket that is occupied by Tyr-71 in the apo-Ras crystal structure, in other words, K-Ras-IN-1 binds directly to K-Ras between switch I and switch II and inhibit Sos-catalyzed K-Ras activation. |
|
V51438 | KRAS G12C inhibitor 20 | 2640858-10-0 | KRAS G12C inhibitor 20 is an inhibitor (blocker/antagonist) of KRAS G12C. |
|
V51429 | KRAS G12C inhibitor 57 | 2821863-70-9 | KRAS G12C inhibitor 57 is a novel, selective, and oral active inhibitor of KRAS G12C that has an IC50 of 0.21 μM in the KRAS G12C/SOS1 binding assay. KRAS G12C inhibitor 57 induces cancer cell apoptosis. |
|
V51435 | KRAS G12C inhibitor 58 | 2915599-52-7 | KRAS G12C inhibitor 58 is an inhibitor (blocker/antagonist) of KRAS G12C and may be utilized in cancer-related research. |
|
V138482 | KRAS G12C inhibitor 65 | 3033305-77-7 | KRAS G12C inhibitor 65 is a potent covalent KRASG12C inhibitor that captures KRASG12C in the GDP-binding state. |
|
V93256 | KRAS G12D inhibitor 25 | 2768099-61-0 | KRAS G12D inhibitor 25 (compound 148) is an inhibitor of KRAS G12C and HSP90α with IC50 of <0.1 μM and 0.1-1 μM, respectively. |
|
V51421 | KRAS G12D inhibitor 7 | 2648552-34-3 | KRAS G12D inhibitor 7 is a potent inhibitor of KRAS G12D (information is from patent WO2021108683, compound 114). |